Further information coming soon:
|Monday Breakfast||Monday Afternoon||Tuesday Breakfast|
|Pierre Fabre Australia||iX Biopharma||Seqirus|
Transitional Pain Medicine: Improving Peri-Hospital Care as a model for long-term change in pain management and opioid prescribing
With the current concern about opioid prescribing and opioid dependence, the postsurgical period remains a critical window with the risk of significant opioid dose escalation, particularly in patients with a history of chronic pain and pre-surgical opioid use. Dr. Clarke will discuss the development and implementation of a Transitional Pain Program that enables close monitoring of pain, opioid medications and mental health vulnerabilities that place certain patients at a higher risk of developing chronic postsurgical pain and progressing to dependence. Beyond in-hospital interventions, he is working to scale the Transitional Pain Program post-discharge, involving community partners to tackle the current public health crises of pain and opioid addiction. Selected cases in which opioid prescribing no longer serves the patients’ pain needs and instead a rotation to buprenorphine/naloxone to manage dependence resulted in pain reduction and improved functioning and quality of life after years of chronic pain, will be presented for discussion.
Dr Hance Clarke is the Director of Pain Services and the Medical Director of the Pain Research Unit at the Toronto General Hospital, Canada. After his medical doctor (MD) and anesthesia subspecialty training in Toronto he received his PhD from the Institute of Medical Sciences at the University of Toronto and is a member of the Royal College Clinician Scientist Program. He is the Research Chair For the University of Toronto Centre For the Study of Pain.
Tuesday 10 April, Morning Session - 7.30 - 8.30 am (includes breakfast)
ActiPatch: wearable, paraesthesia-free, neuromodulation for chronic pain relief
Chronic musculoskeletal pain is prevalent in Australia/New Zealand, and presents significant socio-economic challenges. Chronic pain can be complex to manage, since the level of pain is often unrelated to the level of underlying tissue damage. Existing therapies like drugs/topicals/TENS have limited effectiveness, since they do not target the underlying issue: Central Sensitization, a.k.a. nerve hypersensitivity.
ActiPatch is a wearable, paraesthesia-free neuromodulation device that provides chronic pain relief. Learn how this device uses high-frequency electromagnetic waves to regulate afferent nerve activity and mitigate nerve hypersensitivity. The ActiPatch has distinct advantages over TENS, since it can be used 24/7 and works even over clothing/bandaging.
Dr Sree N. Koneru (Ph. D – VP of Product Development) obtained his Ph.D. in Biomedical Engineering from Binghamton University, NY. His dissertation work involved researching and documenting the physiological responses of human subjects, when stimulated using pulsed radiofrequency fields. This led to the development of advanced electroceutical devices that are capable of providing deep-tissue heat and non-invasively modulating afferent nerve activity. He leads new product development at BioElectronics, with an emphasis on prototype development and validation of efficacy through pilot clinical studies. Dr. Koneru’s primary interest lies in tapping into the potential of non-invasive electroceutical technologies to treat/prevent the onset chronic degenerative diseases.